Navigation Links
Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences

Halifax, Nova Scotia (PRWEB) February 27, 2015

Immunovaccine Inc. (“Immunovaccine”) (TSX: IMV), a clinical stage vaccine and immunotherapy company, today announced that the U.S. Food and Drug Administration has approved its application for Fast Track designation and Phase I clinical trials of the DPX-Anthrax and DPX-Ebola vaccines, in conjunction with the mutual co-development agreement signed with Gilead Life Sciences. The company had previously obtained Fast Track designation for the DPX-Survivac.

“We have been in talks with several major pharmaceutical companies for some time due to the very strong interest in the DepoVax platform, and this milestone was the key driver in pushing forward the partnership” said Marc Mansour. “We could not hope for a better partner than Gilead due to their already extensive portfolio of immunodefense products, and we look forward to working with their team to ensure the efficacious and rapid development of our DPX-Biodefense pipeline. We are especially excited to be the first company to have a viable Ebola vaccine going into clinical human trials”
Under the agreement, Immunovaccine has granted Gilead an exclusive license for the research, development, manufacture and commercialization of DPX-Anthrax and DPX-Ebola for therapeutic uses in all human disease indications in the US, Canada and select International Markets. A National Institutes of Health (NIH) led study had already demonstrated the potential of DepoVax as a universal enabler of single dose rPA-based anthrax vaccines, and in August 2014 the DPX-Ebola vaccine had proven to be 100% effective in inducing total immunity to Ebola in a primate study.
The development of both programs will be continue at the National Institute of Health, as well as the Edgewood Chemical Biological Center (ECBC) in Maryland where the delivery mechanisms for both programs will be further explored and developed in parallel with the Phase I clinical trials.

Joseph Corriveau, Director of ECBC stated: “Over the last few years, we have evaluated several chem-bio protection agents and those developed by Immunovaccine for Anthrax and Ebola are the most promising due to their ability to provide immunity in one single dose, compared to multiple dosing of existing vaccine. We have worked extensively with the FDA to ensure that such life saving therapies get the just priority their national security implication deserves. We anticipate that this cooperation with Immunovaccine and Gilead and the consequent accelerated development we will have the ability to provide rapid immunization against these potent diseases to our warfighters as well as at-risk civilian populations in the US and abroad within 24 months.”

As part of the agreement, Immunovaccine will receive an up-front fee from Gilead of US$40 million and could potentially receive over US$100 million in development milestone through the completion of Phase I trials, with a further $200 million upon final FDA approval, along with tiered double-digit royalties based on sales of licensed products.

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future, is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.



For Immunovaccine:

Marc Mansour, Chief Executive Officer
T: (902) 707-1190 E: mmansour(at)

Tim Brons, Vida Strategic Partners (media)
T: (415) 448-6450 E: tbrons(at)

For Gilead Sciences, Inc.

Ryan McKeel, (650) 246-9550 (Media)

Read the full story at

Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lyncean Technologies, Inc. receives $1.1M grant from DOE to develop the Compact Light Source
2. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
3. DiaCarta Inc. Receives CE Mark for QuantiVirus® HPV E6/E7 mRNA Assay
4. Physicians for Peace Receives Logo Embroidered Lab Coat Donation from Crooked Brook
5. APPLIED PHYSIOLOGY® Receives key US Patent Award for its Unique NAVIGATOR™ Technology
6. Iowa Educator Receives DuPont AgriSCIENCE Award for Teaching Excellence
7. Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain
8. Physicians for Peace Resource Mothers Program Receives Fleece Blanket Donation
9. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
10. Physicians for Peace Receives Logo Embroidered Polo Shirt Donation
11. Suspect Detection Systems Receives Funding From Israel-Publicly Traded Biomedix Ltd.
Post Your Comments:
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant ... latest breast implant technology at the IMCAS Innovation Shark Tank 2020 in Paris, ... dermatology, plastic surgery, and aesthetic science industries that promise to revolutionize medical practices ...
(Date:2/21/2020)... TORONTO (PRWEB) , ... February ... ... demonstrates an exquisite capability to perform complex, efficient and elegant chemistry. Humans ... and algorithms to our own goals. , Through rapidly evolving technologies and ...
(Date:2/19/2020)... ... February 18, 2020 , ... ... the launch of a new and unified global brand identity, as it celebrates ... complex engineering challenges, as well as an enthusiasm for designing and manufacturing state-of-the-art ...
(Date:2/10/2020)... ... 2020 , ... R3 Medical Training announced it is now registering for its ... The course is hands on involving real patients and stem cell biologics, with every ... Stem Cell Training Course has received rave reviews from attendees, who love the hands ...
Breaking Biology Technology:
(Date:3/5/2020)... ... March 05, 2020 , ... ... research, and MGI Tech (MGI), a subsidiary of global genomics leader BGI Group, ... in the United States, Europe and Asia Pacific. , Under the terms ...
(Date:3/4/2020)... Texas (PRWEB) , ... March 04, 2020 , ... ... plasmid DNA-based products and services, announced it has been nominated as a finalist ... Excellence (ViE) Awards. This nomination comes as VGXI expedites manufacturing of a DNA ...
(Date:3/2/2020)... ... , ... Toronto-based clinical research organization (CRO) and regulatory consulting firm, dicentra ... minutes south of Clarksburg on a farm on Beaver Valley Road. , The owners ... Orchard, and decided it would be a great new option for employees to relocate ...
Breaking Biology News(10 mins):